CanVirex04

CanVirex04 is an investigational oncolytic virus therapy being developed by CanVirex, a biotechnology company focused on measles virus-based cancer immunotherapies. The candidate utilizes a measles virus (MV) vector platform, specifically derived from the live-attenuated Schwartz vaccine strain, which is engineered to selectively infect and lyse tumor cells (oncolysis) while simultaneously stimulating a systemic anti-tumor immune response. The platform leverages the natural tropism of the measles virus for receptors often overexpressed on cancer cells, such as CD46 and Nectin-4. CanVirex04 is part of a broader portfolio of MV vectors that may be modified with specific therapeutic payloads to enhance immunogenicity. It is currently in the discovery or early preclinical stage of development for the treatment of solid tumors.